🌿 Anti-Inflammatory Peptides

A synthetic fragment of thymosin beta-4 that promotes cell migration, blood vessel formation, and tissue repair. Often stacked with BPC-157 as the 'Wolverine Stack.'

Dose: 2 mg twice weekly (subcutaneous)

A 28-amino-acid thymic peptide that matures and modulates T-cells. Used internationally as an adjunct in hepatitis, sepsis, and immune-compromised cancer care.

Dose: 1.6 mg twice weekly (subcutaneous)

The C-terminal tripeptide of α-MSH with documented anti-inflammatory activity in IBD and dermatitis preclinical models. Frequently delivered orally and topically.

Dose: 200–500 mcg orally or topical (research only)

An 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.

Dose: Trial range: 1–4 mg subcutaneous daily

The only human cathelicidin antimicrobial peptide. Active against bacteria, viruses, and biofilms. Investigated topically for infected wounds and mucosal infections.

Dose: Trial range: topical or intralesional

A 28-amino-acid neuropeptide with broad immunomodulatory effects. Used clinically (intranasal) by some practitioners for chronic inflammatory response syndrome (CIRS).

Dose: 50 mcg intranasal, 4 times daily (CIRS protocols)

A 15-amino-acid arginate analog developed as a more stable, sometimes more bioavailable alternative to BPC-157. Limited published research; popular among compounding pharmacies in 2025–2026.

Dose: 200–500 mcg daily (subcutaneous)